$0.87
0.89% yesterday
Nasdaq, Nov 25, 10:03 pm CET
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Allakos, Inc. Stock price

$0.87
-0.44 33.68% 1M
-0.55 38.82% 6M
-1.86 68.18% YTD
-0.93 51.73% 1Y
-80.35 98.93% 3Y
-89.88 99.04% 5Y
-30.38 97.22% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.01 0.89%
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Key metrics

Market capitalization $77.62m
Enterprise Value $23.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.07
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-159.09m
Free Cash Flow (TTM) Free Cash Flow $-105.47m
Cash position $92.72m
EPS (TTM) EPS $-2.03
P/E forward negative
Short interest 2.72%
Show more

Is Allakos, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Allakos, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Allakos, Inc. forecast:

2x Buy
33%
3x Hold
50%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Allakos, Inc. forecast:

Buy
33%
Hold
50%
Sell
17%

Financial data from Allakos, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 4.37 4.37
40% 40%
-
-4.37 -4.37
40% 40%
-
- Selling and Administrative Expenses 36 36
13% 13%
-
- Research and Development Expense 115 115
13% 13%
-
-155 -155
9% 9%
-
- Depreciation and Amortization 4.37 4.37
40% 40%
-
EBIT (Operating Income) EBIT -159 -159
10% 10%
-
Net Profit -179 -179
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Allakos, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Allakos, Inc. Stock News

Positive
Seeking Alpha
19 days ago
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demonstrates that the drug may not require frequent dosing, which may be important given potential competition from oral remibrutinib. Upcoming Q1'25 data from a randomized, double-blind, placebo-contr...
Neutral
GlobeNewsWire
20 days ago
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024.
Neutral
GlobeNewsWire
about 2 months ago
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 –
More Allakos, Inc. News

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.

Head office United States
CEO Robert Alexander
Employees 131
Founded 2012
Website www.allakos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today